Sensex

Monday, May 26, 2008

DG - FW: Sharekhan Post-Market Report dated May 26, 2008

 

 

From: The Sharekhan Research Team [mailto:marketwatch@research.sharekhan.com]
Sent: 26 May 2008 17:04
To: The Sharekhan Research Team
Subject: Sharekhan Post-Market Report dated May 26, 2008

 

 

 Sharekhan's daily newsletter

Visit us at www.sharekhan.com

 

May 26, 2008

 

Index Performance

Index

Sensex

Nifty

Open

16,468.32

4,953.60

High

16,498.24

4,953.60

Low

16,300.88

4,858.00

Today's Cls

16,348.50

4,875.05

Prev Cls

16,649.64

4,946.55

Change

-301.14

-71.50

% Change

-1.81

-1.45

 

Market Indicators

Top Movers (Group A)

Company

Price 
(Rs)

%
chg

Gainers

Spice Tele

48.75

8.94

GTL Infra

52.70

5.51

GSK Pharma

1,130.35

5.27

Sun Pharma

1,379.00

3.92

Infosys

1,886.40

3.29

Losers

Bajaj Holdings

598.25

-11.17

Bajaj Hindusthan

199.00

-8.82

IVRCL Infra

381.00

-7.66

Deccan Aviation

119.25

-6.62

Praj Industries

191.40

-6.61

Market Statistics

-

BSE

NSE

Advances

667

183

Declines

2,043

1,034

Unchanged

48

17

Volume(Nos)

25.75cr

43.11cr

 Market Commentary 

Market slumps on weak global cues

Weak international markets coupled with record-high crude oil prices triggered a major sell off with the Sensex dropping over 1.81% at close.

The market continued to remain under the grip of a bear hug for the third straight session and crashed nearly 350 points during intra-day trades, as investors  

 

tracked weak international markets and rise in the global crude oil prices. Continuing from the yesterday's loss of 257 points, the Sensex resumed 180 points lower at 16,468 and lost more ground as trading progressed. The market witnessed a steep fall in early noon trades as selling in heavyweights, Bankex, capital good and metals dragged the index below the 16,300 mark to the day's low of 16,300. After lingering in the negative territory thereafter, the Sensex wrapped up the session at 16,349, down 301 points, while the Nifty shed 72 points to close at 4,875.

Movers & Shakers

  • Hindustan Dorr Oliver moved up on reports that the company has received Rs250 crore-worth order from Vedanta Aluminium.
  • Ashok Leyland inched lower after the company signed three separate joint venture agreements with Nissan Motor of Japan for the development, manufacture and sale of light commercial vehicles and power trains.
  • AI Champdany Industries, which recommended dividend and stock split, ended in the red.


Market breadth was extremely weak. Of the 2,758 stocks traded on the BSE, 2,043 stocks declined while only 667 stocks advanced. The remaining 48 stocks ended unchanged. Except IT and Teck, all the sectoral indices finished in red. The BSE Bankex index was the major loser and declined 3.56% at 7,939 followed by the BSE CG index (down 2.72% at 12,834), the BSE Metal index (down 2.69% at 16,343) and the BSE PSU index (down 2.49% at 7,337).

Barring few select stocks, most frontline stocks faltered under the selling pressure. Among the major laggards JP Associates shed 5.58% at Rs224.40, Ambuja Cement dropped 5.38% at Rs96.65, BHEL slumped 5.21% at Rs1656, Reliance Communications declined 5.08% at Rs543.20, ICICI Bank fell 4.29% at Rs826.70, HDFC tumbled 3.92% at Rs2,573 and Maruti slipped by 3.83% at Rs759.85. Infosys, however, advanced 3.29% at Rs1,886 while Bharti Airtel, TCS and Satyam Computer ended with steady gains.

Among sectoral stocks, Bankex slipped sharply. Federal Bank tumbled 6.09% at Rs221.95, Kotak Bank lost 5.99% at Rs658.05, Indian Overseas Bank fell 4.75% at Rs130.20, Axis Bank declined 4.61% at Rs762.95 and Allahabad Bank shed 4.03% at Rs84.55. Capital goods stocks also bore the brunt and lost ground. Praj Industries, BHEL, Thermax, Bharat Electricals, Alstom, Punj Lloyd, Kirloskar Brothers, Elecon Eng, L&T and Lakshmi Machine crashed over 3-6% each.

Over 1.69 crore Ispat Industries shares changed hands on the BSE followed by IFCI (1.14 crore shares), Aishwarya Telecom (86.54 lakh shares), Spice Telecom (80.18 lakh shares) and RNRL (65.51 lakh shares).

Valuewise, Cairn India was the most actively traded counter on the BSE and registered a turnover of Rs180 crore followed by Reliance Industries (Rs148 crore), Reliance Capital (Rs145 crore), Bajaj Auto (Rs144 crore) and Reliance Power (Rs142 crore).

European Indices at 16:24 IST on 26-05-2008

Index

Level

Change (pts)

Change (%)

FTSE 100 Index

6087.30

-94.30

-1.53

CAC 40 Index

4945.79

12.02

0.24

DAX Index

6946.80

2.75

0.04

Asian Indices at close on 26-05-2008

Index

Level

Change (pts)

Change (%)

Nikkei 225

13690.19

-322.01

-2.30

Hang Seng Index

24127.31

-586.76

-2.37

Kospi Index

1800.58

-27.36

-1.50

Straits Times Index

3103.30

-18.85

-0.60

Jakarta Composite Index

2419.73

-46.23

-1.87

To know more about our products and services, click here.

“This document has been prepared by Sharekhan Ltd. This Document is subject to changes without prior notice and is intended only for the person or entity to which it is addressed to and may contain confidential and/or privileged material and is not for any type of circulation. Any review, retransmission, or any other use is prohibited. Kindly note that this document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction.
Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.
The information contained herein is from publicly available data or other sources believed to be reliable. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees (“SHAREKHAN and affiliates”) are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. We do not represent that information contained herein is accurate or complete and it should not be relied upon as such. This document is prepared for assistance only and is not intended to be and must not alone betaken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. 
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.
SHAREKHAN & affiliates may have used the information set forth herein before publication and may have positions in, may from time to time purchase or sell or may be materially interested in any of the securities mentioned or related securities. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. Any comments or statements made herein are those of the analyst and do not necessarily reflect those of SHAREKHAN.”

To unsubscribe write to myaccount@sharekhan.com

 

__._,_.___
Regards

BigGains !!
Recent Activity
Visit Your Group
Yahoo! Finance

It's Now Personal

Guides, news,

advice & more.

Search Ads

Get new customers.

List your web site

in Yahoo! Search.

Check out the

Y! Groups blog

Stay up to speed

on all things Groups!

.

__,_._,___

DG - Results Analyzed

There have been reports of brisk sales growth and improved margins for the quarter ended March 2008. This year's results have cashed in on domestic market growth, wider product portfolios in regulated market and boost in contract research and manufacturing. Indian companies have around 1.5 percent market share by value and around 12-14 percent by volume, as India exports large quantity of API and low cost generic formulations.

According to Ranjit Kapadia, Head Research (PCG) Prabhudas Lilladher, financial year (FY) 08 belonged to Glenmark Pharma, as it exhibited all round development and growth on all fronts. The company posted a consolidated net Profit After Tax (PAT) of Rs 218.96 crore for the quarter ended March 2008. Main factor that attributed to the growth of this company is the 144 percent growth in the US market and 66 percent growth in global sales of active pharmaceutical ingredients (APIs). GlaxoSmithKline posted a net profit before tax growth of 12 percent compared to previous quarter, while net sales have grown by 5.3 percent on a comparable basis. It can be noticed during the quarter that there was a growth of priority products by nine percent. However, the sales of price controlled products have been impacted by excise drops that are being passed on and consequent price adjustment made due to these changes.

With a backing of strong export thrust and increased domestic sales, Cipla posted a 43 percent growth in the net profit for the quarter ended March 08. Exports that contribute to about 59 percent of Cipla's sales in the quarter saw 23 percent growth, whereas domestic sales on the expanded base saw 13 percent growth. The company's net profit increased by 42.7 percent to Rs 179.5 crore from Rs 125.7 crore during the corresponding quarter in the previous year. Cipla also reported 19.5 percent rise in net sales to Rs 1,112 crore for the last quarter against Rs 938.5 crore reported during the same quarter in the previous year.

Other company that saw a steady rise is Hikal. It saw an increase of 29 percent in sales as the sales for the year ended 31st March 2008 were at Rs 301 crore as compared to Rs 234 crore in the previous year. The profit after tax also increased as it was at Rs 49.8 crore as compared to Rs 33.8 crore in the previous year in spite of appreciation of Rupee. Jai Hiremath, Vice Chairman and Managing Director, Hikal, said that it is for the first time that the sales in pharma business have surpassed the crop protection business. He added that efforts on restructuring of Marsing is on track and on a consolidated basis, the turnover was Rs 461 crore as compared to Rs 428 crore last year and PAT was Rs 48.9 crore as compared to Rs 26 crore in the previous year.

Zydus Cadila also posed an impressive result for the year ended March 08. It registered an increase of 27 percent, a total operating income of Rs 2,325 crore from last year. The net operating profit for the same period is up by 23 percent at Rs 254 crore. The main factor that had led to this growth is the 72 percent growth in formulation exports, 13 percent growth in domestic branded formulation business and 131 percent growth in animal health business.

In the limelight

Nicholas Piramal India Limited (NPIL) who had projected a growth at 16 percent in the current fiscal year. Total operating income on consolidated basis for the quarter ended 31 March 2008 was up by 19 percent to Rs 7.7 billion over Q4 FY 07. Operating profit increased by 139.9 percent to Rs 2.0 billion. Net profit for the quarter was up by 141.7 percent to Rs 1.3 billion. During the quarter, NPIL's domestic branded formulations business reported strong growth of 17.9 percent, with revenues of Rs 3.1 billion. The company's domestic business has thus registered an aggregate growth of 15 percent during the last three quarters of FY 2008. The company's custom manufacturing (CMG) revenues grew 15.3 percent to Rs 3.9 billion during Q4 FY 2008. Custom manufacturing revenues from facilities in India grew during Q4 FY 2008 by 224 percent to Rs 736 million, compared to Rs 227 million in Q4 FY2007.

Over the last six years, Ajanta Pharma has registered compounded annual growth rate (CAGR) of 26 percent in sales and 45 percent in profits. Ajanta Pharma also saw increase in its consolidated net profit by 49 percent to Rs 21.88 crore as compared to previous year's Rs 14.66 crore. Its consolidated income has also grown by 19 percent to Rs 317.48 crore compared to previous year's Rs 267.31. For the quarter ended 31st March, 2008, total income stood at Rs 87.28 crore against last year's Rs 80.10 crore, while net profit increased by 14.84 percent to Rs 8.75 crore against Rs 7.62 crore of last year.

Alembic reported net sales for the year ended March 31, 2008 at Rs 1,027 crore that is up 42 percent compared to Rs 722 crore in the previous year. The net profit for the year ended March 31, 2008 rose by 59 percent to Rs 112 crore, as against Rs 71 crore posted in last fiscal. Sales for the fourth quarter stood at Rs 268 crore, a growth of 58 percent as compared to Rs 169 crore in the corresponding quarter of the previous year. The company reported a net profit of Rs 15.34 crore for the quarter ended March 31, 2008, a jump of 39 percent as against Rs 11.05 crore posted in the same period of last fiscal. The company's efforts in the last few quarters to break into regulated markets have started yielding results. The company's annual sales to regulated markets was Rs 189.02 crore against 49.87 crore in last fiscal, while quarterly sales were Rs 71.72 crore against last year's Rs 11.25 crore.

Some pharma companies showcased a decent performance one of which is Plethico Pharma Ltd (PPL). It reported a decent performance during the last quarter for the year ended December 2007. This year, PPL changed its year ending from September 30 to Dec 31. Therefore FY 07 would be a 15-month period. Its top line grew by 48.1 percent y-o-y to Rs 1203.2 million during the quarter ended December 2007. On a cumulative basis for 15M FY 07, total revenue increased by 35.3 percent y-o-y to Rs 5554.4 million. For the quarter ended December 2007, PPL reported Earnings Before Depreciation, Interest, Taxes and Amortization (EBDITA) growth of 45.3 percent y-o-y to Rs 344.2 million compared to Rs 236.9 million in corresponding quarter last year. For 15 M FY 07, EBDITA growth stood at 32.1 percent y-o-y to Rs 1628.0 million. However, PPL's overall EBDITA margin for the period declined by 110 basis points to 28.8 percent. PPL recorded 51.9 percent y-o-y growth at net profit level to Rs 299.8 million during the quarter ended December 2007 and 49.7 percent y-o-y growth to Rs 1583.3 million for 15 M FY07.

Though comparatively, this quarter has been fruitful for most pharmacos, there are some who had to face setbacks. Hyderabad based Suven Life Sciences saw a 33 percent fall in the net profit to Rs 1.94 crore in the fourth quarter for the year ended March 2008 compared to Rs 2.91 crore last year. However, although there is a decrease in net profit, revenues had increased 22.67 percent to Rs 35.16 crore ie Rs 28.66 crore. Rupee appreciation is one factor that has affected revenues.

Roadblocks

Recent changes in regulatory framework to report market losses due to currency fluctuations and derivative trading has led to forex losses. Moreover, the rupee has weakened against the dollar by 1.8 percent during the quarter and this has led companies to make provisions for currency fluctuations and translation losses. Kapadia says, "The government's move to bring more products under price control could adversely affect sales and profitability of pharma. The rise in rupee against the dollar can reduce export revenues and would affect sales and profitability of exporting companies."

Pharma trends

The current analysis of results shows that pharma companies who have posted good results have fared very well in domestic and unregulated markets. One place that saw a downfall was in the exports. Only few companies like Cipla gained from exports. Gains from exports were comparatively less, mainly due to rupee appreciation. Many companies have hived of their R&D units so as to transfer expenses related to R&D to the new entity. "As R&D expenses were eligible for 150 percent weighted average deduction, the main company will not be able to claim this deduction. However, due to other tax benefits, tax liability is not likely to increase. Hence, profitability of these companies is likely to improve. Most of the R&D companies are likely to report losses in the initial years due to lack of recurring income. The companies will have to depend on milestone payments on licensing molecules," says Kapadia.

Current results are very satisfying for almost all, but one thing that comes to our mind is how will companies be utilising funds and profits for their benefit. Most companies will be utilising it for expansion and investment in R&D. Kapadia points out that most companies are expanding their activities in Special Economic Zones (SEZ) as after FY 2010, Export Oriented Unit (EOU) benefits will not be available to the companies. On the acquisition front, most recent acquisitions have been done overseas. The likely financing route for overseas acquisition is through American Depository Receipt (ADR)/Global Depositary Receipt (GDR) or Foreign Currency Convertible Bond (FCCB). For the fund requirement for the domestic market, preferential allotment of shares and Initial Public Offering (IPO) are the most preferred routes.

Looking to the future

With a view for expansion and creating a mark the Indian pharmacos are looking at developing countries where regulations are not very stringent and margins are better than in the domestic market. Companies can also introduce branded generics in some of these markets. Therefore, Japan is the new destination as the Japanese government encourages the use of generic products.

Kapadia avers, "The domestic market is likely to grow by 13-15 percent unless the government brings more products under price control. Pharmacos are likely to face competition in US market due to the economic slowdown and severe competition among generic products." He predicts, "The sharing of 180-days exclusivity period by more than one company will also put pressure on prices. Moreover, authorised generics will also limit profitability of generic players in this. The opening of Japanese pharma market is likely to offer good opportunity for the Indian pharma companies."

 

__._,_.___
Regards

BigGains !!
Recent Activity
Visit Your Group
Yahoo! Finance

It's Now Personal

Guides, news,

advice & more.

Search Ads

Get new customers.

List your web site

in Yahoo! Search.

Yahoo! Groups

w/ John McEnroe

Join the All-Bran

Day 10 Club.

.

__,_._,___